Your browser doesn't support javascript.
loading
Indian experience with immunotherapy in sarcoma and gastrointestinal stromal tumors: a retrospective study.
Reddy, Rohit; Velagapudi, Raja Mounika; Chitikela, Sindhura Durga; Barwad, Adarsh; Shrivastava, Shakti; Dhamija, Ekta; Shamim, Shamim Ahmed; Tripathy, Sarthak; Pandey, Rambha; Rastogi, Sameer.
Afiliación
  • Reddy R; Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Velagapudi RM; Department of Internal Medicine, Venkateshwara Institute of Medical Sciences, Uttar Pradesh, 244236, India.
  • Chitikela SD; Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Barwad A; Department of Pathology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Shrivastava S; Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Dhamija E; Department of Radio diagnosis, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Shamim SA; Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Tripathy S; Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Pandey R; Department of Radiation Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
  • Rastogi S; Sarcoma Medical Oncology Clinic, Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, 110029, India.
Future Sci OA ; 8(5): FSO795, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35662745
ABSTRACT

Aim:

To study the role of check point inhibitors (CPI) in sarcoma and gastrointestinal stromal tumors. Materials &

methods:

Retrospective data of 15 patients diagnosed with advanced sarcoma or gastrointestinal stromal tumors and treated with CPI.

Results:

3/14 patients (21.4%) responded to treatment with a disease control rate of 42.8% (6/14). After a median follow-up of 14 months (range 2-24 months), 11 (73.3%) patients progressed, the median progression-free survival was 4 months (95% CI 1.7-6.3) and median overall survival was 14 months (95% CI 2.6-25.7). Only one patient experienced a grade IV adverse event.

Conclusion:

Our data represent the first real-world application of CPI in sarcoma from India. We believe that CPI should be further evaluated in clinical trials.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Future Sci OA Año: 2022 Tipo del documento: Article País de afiliación: India
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Future Sci OA Año: 2022 Tipo del documento: Article País de afiliación: India